Munich - Delayed Quote EUR

Ono Pharmaceutical Co., Ltd. (ON4.MU)

9.35

0.00

(0.00%)

As of 5:27:00 PM GMT+2. Market Open.

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV). PV is a rare hematologic disease characterized by the overproduction of red blood cells, significantly increasing the risk of serious blood clots, especially in critical organs like the lungs, heart and brain. S

Benzinga 2 months ago

IONS

OPHLY
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

Zacks 2 months ago

IONS

OPHLY
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

Zacks 2 months ago

FATE

OPHLY
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo

Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio.

Pharmaceutical Technology 3 months ago

4568.T

OPHLY

Performance Overview

Return	ON4.MU	Nikkei 225 (^N225)
YTD	-132.99%	-6.85%
1-Year	-89.52%	-4.97%
3-Year	-94.21%	+37.62%